Announcement on Voluntary Disclosure of BGM1812 Injection Obtaining US. FDA Approval for Drug Clinical Trial

About this update from Brightgene Bio-medical Technology Co. Ltd. Class A

Announcement on Voluntary Disclosure of BGM1812 Injection Obtaining US. FDA Approval for Drug Clinical TrialThe abstract is for reference only. Please refer to the full text of the announcement on the very day.Link of Full Text for Reference: View Attachment

View stock analysis, news, and events for Brightgene Bio-medical Technology Co. Ltd. Class A